Distinguished scientists and members of the medicalprofession discuss the research and development of safe andsuitable drugs for the long-term treatment of chronicdiseases. The book provides an up-to-date survey on newinsights and technologies - as well as ethicalconsiderations - , since traditional means and methods ofdrug research and drug development may no longer suffice tomeet the challenges of the next century.
Distinguished scientists and members of the medicalprofession discuss the research and development of safe andsuitable drugs for the long-term treatment of chronicdiseases. The book provides an up-to-date survey on newinsights and technologies - as well as ethicalconsiderations - , since traditional means and methods ofdrug research and drug development may no longer suffice tomeet the challenges of the next century.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Atherosclerosis and Coronary Heart Disease.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Alzheimer's Disease.- Obstructive Lung Disease.- Biological Approaches to Cancer Therapy.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- The Impact of Clinical Trials on Clinical Practice.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Leukotrienes in Airways and Blood Vessels.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Protein Crystallography and Drug Design.- Applying Engineering Principles to the Design of Cellular Biology.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Mechanisms of Cancer Metastasis.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- The Functions of Ethical Committees.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.
History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Atherosclerosis and Coronary Heart Disease.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Alzheimer's Disease.- Obstructive Lung Disease.- Biological Approaches to Cancer Therapy.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- The Impact of Clinical Trials on Clinical Practice.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Leukotrienes in Airways and Blood Vessels.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Protein Crystallography and Drug Design.- Applying Engineering Principles to the Design of Cellular Biology.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Mechanisms of Cancer Metastasis.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- The Functions of Ethical Committees.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
